ESMO 2021: Cabozantinib for collecting duct carcinoma – the BONSAI study
Metastatic collecting duct carcinoma is an aggressive form of RCC, [...]
Metastatic collecting duct carcinoma is an aggressive form of RCC, [...]
Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of [...]
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
The cabozantinib/nivolumab combination has been shown to be effective at [...]
Cell metabolism in renal cell carcinoma (RCC) tumours is disrupted, [...]
The cabozantinib/nivolumab combination has been shown to be effective at [...]
The European Commission has approved the use of the nivolumab [...]
The Committee for Medicinal Products for Human Use (CHMP) of [...]
A gene called MET codes for a protein called MET [...]
In a small phase 2 study presented at the virtual [...]